Sotera Health price target raised to $17 from $13 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Sotera Health (SHC) to $17 from $13 and keeps an Overweight rating on the shares following the Q2 report. The firm believes the shares are undervalued on the core business but that Sotera’s litigation overhang limits what investors are willing to pay.